Based on these findings, we hypothesize that missense mutations in NTRK1 and ZRSR2 may contribute to primary resistance to Osimertinib in non‐small cell lung cancer (NSCLC) with EGFR mutations through modulation of the PI3K pathway. Here, ZRSR2 is linked to non-small cell lung carcinoma.